Compare Bristol-Myers Squibb Co (BMY) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Waste Management, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.78 (market cap $129.94B), while Waste Management, Inc. trades at $226.05 (market cap $90.68B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | WM | |
|---|---|---|
Market Cap | $129.94B | $90.68B |
Sector | Health | Industrials |
52-Week High | $65.89 | $246.51 |
52-Week Low | $42.60 | $196.77 |
Enterprise Value | $163.92B | $113.47B |
Dividend Yield | 3.96% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
WM trades at $227.2, up 0.26% on the day, with a neutral technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.02, beating estimates, and maintains robust profitability with a net income margin of 11.12%. Revenue growth is steady, reaching $25.20B in 2025, though valuation multiples like a P/E of 59.74 appear elevated. Recent news highlights institutional trading activity and earnings focus on pricing discipline.
The outlook is positive with a consensus price target of $263.43, implying 16% upside, supported by 57% buy ratings. Risks include high debt levels and sensitivity to economic cycles, but consistent cash flow generation and margin gains provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
